CXCL13/BLC/BCA-1 Antibody (53602) [Unconjugated]

CXCL13/BLC/BCA-1 was detected in immersion fixed paraffin-embedded sections of human tonsil using Mouse Anti-Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB8012) at 1.7 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Recombinant Human CXCL13/BLC/BCA-1 (801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (AR002). Chemotaxis elicited by Recombinant Human CXCL13/BLC/BCA-1 (0.05 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB8012). The ND50 is typically 0.5‑2.5 µg/mL.

Immature dendritic cells (CD14 selected PBMCs are treated with 20 ng/mL Recombinant Human IL-4 Protein (204-IL) and 50 ng/mL Recombinant Human GM-CSF Protein (215-GM) for 6 days) were stained with Mouse Anti-Human CXCL13/BLC/BCA‑1 Monoclonal Antibody (Catalog # MAB8012, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (FC012). View our protocol for Staining Intracellular Molecules.

Immature dendritic cells (CD14+ selected PBMCs are treated with 20 ng/mL Recombinant Human IL-4 Protein (204-IL) and 50 ng/mL Recombinant Human GM-CSF Protein (215-GM) for 6 days) were stained with Mouse Anti-Human CD11c PE‑conjugated Monoclonal Antibody (Catalog # FAB1777P) and either (A) Mouse Anti-Human CXCL13/BLC/BCA‑1 Monoclonal Antibody (Catalog # MAB8012) or (B) Mouse IgG1 Isotype Control (Catalog # MAB002) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012). View our protocol for Staining Intracellular Molecules.

TT cells were stained with Mouse Anti-Human CXCL13/BLC/BCA‑1 Monoclonal Antibody (Catalog # MAB8012, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012). View our protocol for Staining Intracellular Molecules.

• Reactivity: Hu
• Applications: IHC, B/N, Flow
• Clone: 53602
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

CXCL13/BLC/BCA-1 Antibody (53602) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human CXCL13/BLC/BCA-1
  Val23-Arg94
  Accession # O43927
• Specificity: Detects human CXCL13/BLC/BCA-1 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 1-25 ug/mL
  • Intracellular Staining by Flow Cytometry 0.25 ug/10^6 cells
  • Neutralization 0.5-2.5 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL13/BLC/BCA-1 Antibody (53602) [Unconjugated]

• ANGIE
• ANGIE2
• B cell-attracting chemokine 1
• B lymphocyte chemoattractant
• BCA1
• BCA-1
• BCA1B-cell chemoattractant
• BCA-1CXC chemokine BLC
• B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1)
• BLC
• BLCSmall-inducible cytokine B13
• BLR1L
• B-lymphocyte chemoattractant
• chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant)
• chemokine (C-X-C motif) ligand 13
• C-X-C motif chemokine 13
• CXCL13
• SCYB13
• SCYB13B-cell-attracting chemokine 1
• small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cellchemoattractant)

Background

CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23-34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA-1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.

1. Gunn, M.D. et al. (1998) Nature, 391:799.
2. Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
3. Forster, R. et al. (1996) Cell 87:1037.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCL13/BLC/BCA-1 Antibody (MAB8012)(1)

Publication using MAB8012

• Liu, Y;Ye, SY;He, S;Chi, DM;Wang, XZ;Wen, YF;Ma, D;Nie, RC;Xiang, P;Zhou, Y;Ruan, ZH;Peng, RJ;Luo, CL;Wei, PP;Lin, GW;Zheng, J;Cui, Q;Cai, MY;Yun, JP;Dong, J;Mai, HQ;Xia, X;Bei, JX; Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma Nature communications 2024-09-04 [PMID: 39231979] (Immunohistochemistry, Human)

Bioinformatics

• Uniprot:
  • O43927()